Literature DB >> 31630564

Direct anterior approach versus posterior approach in primary total hip replacement: comparison of minimum 2-year outcomes.

David R Maldonado1, Cynthia Kyin1, Rafael Walker-Santiago1, Philip J Rosinsky1, Jacob Shapira1, Ajay C Lall1, Benjamin G Domb1.   

Abstract

INTRODUCTION: The direct anterior approach (DAA) has gained popularity in recent years for total hip arthroplasty (THA). Several authors reported significantly better early outcomes when compared to the posterior approach (PA). Nevertheless, controversy exists regarding longer-term benefits of the DAA.
METHODS: Data was prospectively collected and retrospectively reviewed for primary THAs conducted between July 2008 and July 2016. Patients who underwent DAA and PA with minimum 2-year follow-up for Harris Hip Score (HHS), Forgotten Joint Score-12 (FJS-12), Veteran RAND 12 Mental (VR-12 Mental), Veteran RAND 12 Physical (VR-12 Physical), 12-Item Short Form Survey Mental (SF-12 Mental), 12-Item Short Form Survey Physical (SF-12 Physical), visual analogue scale, and patient satisfaction were included. Propensity score matching was performed on the DAA and PA cohorts (1:1) based on the following variables: age, sex, body mass index, and laterality.
RESULTS: 205 DAA hips were satisfactorily matched to 205 PA hips. The DAA group had higher scores at final follow-up for VR-12 Mental (p = 0.0145), VR-12 Physical (p = 0.0236), SF-12 Mental (p = 0.0393), and SF-12 Physical (p = 0.0391). The DAA and PA groups had comparable HHS (p = 0.0737) and FJS-12 (p = 0.2900).
CONCLUSIONS: Although the DAA and PA groups had different follow-up periods, both the DAA and PA groups reported favourable outcomes at minimum 2-year follow-up. While both groups achieved comparable scores for the majority of PROs including VAS and patient satisfaction, the DAA group achieved superior quality of life outcomes when compared with a propensity score matched group of PA surgeries.

Entities:  

Keywords:  Direct anterior approach; posterior approach; total hip arthroplasty

Mesh:

Substances:

Year:  2019        PMID: 31630564     DOI: 10.1177/1120700019881937

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  7 in total

1.  Effect of Marital Status on Outcomes Following Total Joint Arthroplasty.

Authors:  Ran Schwarzkopf; Vivek Singh; Benjamin Fiedler; David N Kugelman; Morteza Meftah; Vinay K Aggarwal
Journal:  Arch Orthop Trauma Surg       Date:  2021-05-25       Impact factor: 3.067

2.  Direct anterior approach in total hip arthroplasty: influence of stem length on clinical and radiological outcomes at medium-term follow-up.

Authors:  Salvatore Risitano; Alice Piccato; Federico Fusini; Lorenzo Rissolio; Marco Marcarelli; Gianmarco Bosa; Pier Francesco Indelli
Journal:  Musculoskelet Surg       Date:  2022-08-19

3.  Good long-term outcomes for Direct Anterior Approach Total Hip Arthroplasty in South Africa.

Authors:  Jurek Rafal Tomasz Pietrzak; Zia Maharaj; Josip Nenad Cakic
Journal:  J Orthop       Date:  2020-08-28

4.  Comparison of direct anterior approach and posterior approach total hip arthroplasty: More than 5-year follow-up.

Authors:  Takahito Yuasa; Kohei Aoki; Motoshi Gomi; Kohei Shiota
Journal:  J Orthop       Date:  2021-03-29

5.  Risk factors for femoral fracture in lateral decubitus direct anterior approach total hip arthroplasty using conventional stems: a retrospective analysis.

Authors:  Guanjun Sun; Yi Yin; Yongjie Ye; Qingshan Li
Journal:  J Orthop Surg Res       Date:  2021-01-30       Impact factor: 2.359

6.  Impact of Intrathecal Fentanyl on Hospital Outcomes for Patients Undergoing Primary Total Hip Arthroplasty With Neuraxial Anesthesia.

Authors:  McKayla Kelly; Justin Turcotte; Jacob Aja; James MacDonald; Paul King
Journal:  Arthroplast Today       Date:  2021-04-14

7.  Failure to Meet Same-Day Discharge is Not a Predictor of Adverse Outcomes.

Authors:  Vivek Singh; Afamefuna M Nduaguba; William Macaulay; Ran Schwarzkopf; Roy I Davidovitch
Journal:  Arch Orthop Trauma Surg       Date:  2021-06-01       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.